Persons Reported to be living with HIV infection and with AIDS reported
Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 29 229 0 1 29 230 258 1 259
2001 43 238 0 1 43 239 281 1 282
2002 88 251 2 2 90 252 339 4 342
                   

 

HIV Infection Cases  from areas with confidential HIV infection reporting
Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 26 30 0 30
2001 15 48 1 49
2002 41 88 2 90
         


 

Adult/Adolescent HIV infection and AIDS cases reported in the United States
Year Males Females
  HIV AIDS HIV AIDS
2000 16 20 6 6
2001 15 5 3 10
         
         


 

Pediatric AIDS cases reported

Year
2000 0
2001 0
2002 2
   


 

Alaska: Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 530
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 525
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 5

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through 2002
  AK USA
Men 433 680,909
Women 69 146,298
Total 502 827,208

 

Alaska: New AIDS Cases

New AIDS Cases, Reported in 2002 33
New Adult/Adolescent AIDS Cases, Reported in 2001 18
New AIDS Cases in Children <13, Reported through December 2001 0

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001
  AK USA
Men 15 31,901
Women 3 11,082
Total 18 42,983

 

Alaska: Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 252
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 251
Estimated Number of Children Living with AIDS at the End of 2002 2
HIV Infection Cases Reported in 2002 41

 

Total Deaths in Alaska Reported through 2000, due to AIDS = 258
 
HIV Reporting Requirements ?   Yes, Name based reporting.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions: Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?  Voluntary HIV testing; no specific law. State follows CDC guidelines; No specific law or language on testing for mothers and newborns.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration? NO
Definitions: 1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 
Sterile Syringe Exchange Programs?  Yes

Notes: U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  Yes, No state-specific content requirements
 
Minors' Right to Consent to HIV/STD Services?  Yes
 
 
Total Ryan White Funding, FY2000   $1,121,741  FY2002  $2,088,958

CDC HIV Prevention Funding for States
 FY2001 $1,431,418 

FY2003   $1,482,135

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation

Total ADAP Clients Served, June 2002  
  AK
#		 US
#
   32 80,035

 
ADAP Clients Served by Sex, June 2002  
  AK
#		 AK
%		 US
#		 US
%
  Male 21 67 62,034 78
  Female 10 31 16,702 21
  Total 32 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  AK
#		 AK
%		 US
#		 US
%
  White 21 65 29,426 37
  Black 0 0 26,245 33
  Hispanic 10 31 19,883 25
  Asian/Pacific Islander 1 2 795 1
  American Indian/Alaskan Native 1 2 795 1
  Other 0 0 795 1
  Total 32 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  AK
#		 AK
%		 US
#		 US
%
  <13 years old 0 0 795 1
  13-19 years old 0 0 0 1 0 1
  20-44 years old 21 67 50,105 63
  >44 years old 11 33 27,836 35
  Total 32 100 79,531 100

 
ADAP Clients Served by Income, June 2002  
  AK
#		 AK
%		 US
#		 US
%
  <100% FPL 15 48 38,175 48
  101-200% FPL 14 43 26,245 33
  201-300% FPL 3 9 8,748 11
  301-400% FPL 0 0 3,181 4
  >400% FPL 0 0 1,591 2
  Total 32 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  AK
#		 AK
%		 US
#		 US
%
  Medicaid 0 0 0 10
  Medicare 3 10 0 6
  Private 11 33 0 13

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  AK
$		 US
$
   490,440 878,610,754

 

National ADAP Budget by Source, FY 2002  
  AK
$		 AK
%		 US
$		 US
%
  ADAP Earmark 397,076 81 619,830,000 71
  Title II Base 0 0 28,886,192 3
  State 0 0 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 93,364 19 30,941,439 4
  ADAP Supplemental Grants 0 0 19,170,000 2
  Total 490,440 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  AK
$		 US
$
   27,709 70,705,142

 

ADAP Drug Expenditures by Drug Class, June 2002  
  AK
$		 AK
%		 US
$		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 14,217 51 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 5,706 21 7,940,575 12
  Protease Inhibitors 6,488 23 16,433,502 25
  Opportunistic Infections/Other 1,298 5 9,015,329 14
  Total 27,709 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  AK
#		 US
#
   93 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  AK
#		 AK
%		 US
#		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 39 42 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors 17 18 23,933 10
  Protease Inhibitors 17 18 33,813 15
  Opportunistic Infections/Other 20 22 87,746 38
  Total 93 100 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  AK
$		 US
$
   54,300 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  AK
#		 US
#
  Nucleoside Reverse Transcriptase Inhibitors 9 NA
  Protease Inhibitors Covered 6 NA
  Non-nucleosides Covered 3 NA
  OI Prophylaxis Covered 14 NA
  Other Medications Covered 30 NA
  Total 62 NA

 
ADAP Emergency Cost Containment Measures, February 2003  
  AK
 		 US
 
  Has ADAP Emergency Cost Containment Measures in Place No 16 Yes